What the FDA labels say about taking them together
Cidofovir and tobramycin
Cidofovir's FDA label of October 25, 2023 names tobramycin in its drug interactions section; the tobramycin labels PlainMeds reads (4) do not name cidofovir. The cidofovir label: “Nephrotoxic agents Concomitant administration of cidofovir injection and agents with nephrotoxic potential [e.g., intravenous aminoglycosides, amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and …”
Check it at the source: the cidofovir FDA label on DailyMed (effective October 25, 2023, Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.); the tobramycin FDA label on DailyMed (effective November 1, 2023, Bausch & Lomb Incorporated).
What does the cidofovir label say about tobramycin?
Cidofovir label, drug interactionsNephrotoxic agents Concomitant administration of cidofovir injection and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and nonsteroidal anti-inflammatory agents] is contraindicated.
Cidofovir label, warningsThe safety of cidofovir injection has not been evaluated in patients receiving other known potentially nephrotoxic agents, such as intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents (see DOSAGE AND ADMINISTRATION ).
Source: FDA drug label (CIDOFOVIR DIHYDRATE), Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc., effective October 25, 2023 (SPL set 44966a7e-d777-40fb-956f-d0f31f737848), via openFDA; the full label on DailyMed
What does the tobramycin label say about cidofovir?
Tobramycin's label (effective November 1, 2023) and its 3 other brand-application labels do not name cidofovir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Tobramycin), Bausch & Lomb Incorporated, effective November 1, 2023 (SPL set a5693ec9-d2f7-4d45-90b0-a113c54840d7), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cidofovir | Tobramycin | |
|---|---|---|
| Labeled for | n/a | Bacterial infections, Urinary tract infections |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | n/a | $1.08 per mL 300 mg/5 mL ampule |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once